After Sanofi leadership telegraphed an upsized appetite for business development last month, signals have emerged that the ...
Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the early 2030s, as the ...
The FDA has slammed Johnson & Johnson over misleading claims about its bladder cancer drug Inlexzo, accusing the pharma ...
Biogen is visualizing life amid disease progression in its newest Friedreich ataxia (FA)-focused campaign, reminding ...
Underscoring how crowded the U.S. market for generalized myasthenia gravis (gMG) has become, the FDA on Wednesday approved ...
Lotte Biologics, a South Korea-headquartered CDMO established in 2022, has inked a large manufacturing deal with an unnamed ...
Salerno Pharmaceuticals of Tulsa, Oklahoma, is facing pressure from the FDA to yank its lone commercial product. | In a ...
After delaying the phase 3 readout of its Alzheimer’s psychosis program for Cobenfy earlier this year, Bristol Myers Squibb ...
Beren Therapeutics has officially seen a cyclodextrin therapy across the finish line, scoring an FDA approval in Niemann-Pick disease type C (NPC) that’s over a decade in the making.
No breast cancer asset in Roche’s pipeline carries a higher valuation than giredestrant. | Roche’s giredestrant took the ...
The White House is reportedly pulling the nomination for Heidi Overton, M.D., Ph.D., to lead the FDA just hours before the ...
In a complete response letter (PDF) dated Nov. 13 and newly published on the FDA’s website, reviewers at the agency flagged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results